PMID- 12151064
OWN - NLM
STAT- MEDLINE
DCOM- 20021125
LR  - 20220409
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 30
IP  - 1
DP  - 2002 Aug 22
TI  - Stability-indicating HPLC assays for the determination of prilocaine and procaine 
      drug combinations.
PG  - 49-58
AB  - Stability-indicating, reversed phase high-performance liquid chromatographic 
      (HPLC) methods have been developed for the determination of several procaine 
      hydrochloride and prilocaine hydrochloride combinations. The separation and 
      quantitation of epinephrine-prilocaine and epinephrine-procaine drug combinations 
      were achieved on a phenyl column using a mobile phase of 80:20% v/v 25 mM 
      phosphate buffer (pH 3.0) containing 50 mM heptanesulfonic acid sodium 
      salt-acetonitrile at a flow rate of 1 ml x min(-1) and UV detection at 254 nm. 
      The method showed linearity for the epinephrine and prilocaine hydrochloride 
      mixture in the 0.25-2.5 and 8-200 micro g ml(-1) ranges, respectively. The intra- 
      and inter-day relative standard deviations (RSDs) ranged from 0.26 to 2.05% and 
      0.04 to 0.61% for epinephrine and prilocaine hydrochloride, respectively. The 
      epinephrine and procaine hydrochloride mixture yielded linear ranges of 0.25-2.0 
      and 5-100 micro g ml(-1) and intra- and inter-day RSDs ranged from 0.23 to 1.88% 
      and 0.07 to 0.26% for epinephrine and procaine hydrochloride, respectively. The 
      assays were shown to be suitable for measuring epinephrine-prilocaine and 
      epinephrine-procaine combinations in their respective injection dosage forms. 
      Stability-indicating HPLC assays were also developed for several other procaine 
      drug combinations since their monographs are present in the USP 24; however, 
      quantitation was not investigated since these combinations are not commercially 
      available. A mobile phase consisting of 80:20% v/v 25 mM phosphate buffer (pH 
      3.0) containing 50 mM heptanesulfonic acid-acetonitrile was utilized for the 
      levonordefrin-tetracaine-procaine drug combination, while a mobile phase 
      consisting of 70:30% v/v 25 mM phosphate buffer (pH 3.0) containing 50 mM 
      heptanesulfonic acid sodium salt-acetonitrile was utilized for the separation of 
      levonordefrin-procaine-propoxycaine and norepinephrine-procaine-propoxycaine. All 
      separations were achieved on a phenyl column at a flow rate of 1 ml x min(-1) and 
      UV detection at 254 nm.
FAU - Storms, Meredith L
AU  - Storms ML
AD  - Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, 
      University of Georgia, Athens, GA 30602-2352, USA.
FAU - Stewart, James T
AU  - Stewart JT
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Anesthetics, Local)
RN  - 0 (Drug Combinations)
RN  - 0 (Indicators and Reagents)
RN  - 0 (Pharmaceutical Solutions)
RN  - 046O35D44R (Prilocaine)
RN  - 4Z8Y51M438 (Procaine)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Anesthetics, Local/*analysis
MH  - Chromatography, High Pressure Liquid
MH  - Drug Combinations
MH  - Drug Stability
MH  - Indicators and Reagents
MH  - Norepinephrine/analysis
MH  - Pharmaceutical Solutions
MH  - Prilocaine/*analysis
MH  - Procaine/*analysis
MH  - Reference Standards
MH  - Spectrophotometry, Ultraviolet
EDAT- 2002/08/02 10:00
MHDA- 2002/11/26 04:00
CRDT- 2002/08/02 10:00
PHST- 2002/08/02 10:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/08/02 10:00 [entrez]
AID - S0731708502001954 [pii]
AID - 10.1016/s0731-7085(02)00195-4 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2002 Aug 22;30(1):49-58. doi: 10.1016/s0731-7085(02)00195-4.